Clinical Trial

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)

Study acronym: NESSIE
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 14, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and safety of Sintilimab combined with IBI310 and Surufatinib for the treatment of high-grade advanced-neuroendocrine neoplasm
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-12-07.
Trial Details
NCT Number NCT05165407
Lead Sponsor Peking University
Conditions Neuroendocrine Neoplasm
Enrollment 30 participants
Start Date 2022-07-12
Primary Completion 2025-09 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2025-03-14